Publications

Bibliography

Full length, peer-reviewed, original articles:
  • Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. “Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis”. American journal of kidney diseases: the official journal of the National Kidney Foundation. 2009;54(3):542-5.
  • Leung N, Eirin A, Irazabal MV, Maddox DE, Gunderson HD, Fervenza FC, et al. “Acute kidney injury in patients with inactive cytochrome P450 polymorphisms”. Ren Fail. 2009;31(8):749-52.
  • Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. "Rituximab therapy in idiopathic membranous nephropathy: a 2-year study." Clinical journal of the American Society of Nephrology: CJASN. 2010; 5(12):2188-98.
  • Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, et al.Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience”. Transplantation. 2011;91(12):1370-5.
  • Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, et al.Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease”. Kidney international. 2011;80(3):295-301.
  • Irazabal MV, Huston J, 3rd, Kubly V, Rossetti S, Sundsbak JL, Hogan MC, et al.Extended follow-up of unruptured intracranial aneurysms detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease”. Clinical journal of the American Society of Nephrology: CJASN. 2011;6(6):1274-85.
  • Irazabal MV, Torres VE. “Poliquistosis  Renal Autosomica Dominante” Nefrologia. doi:10.3265/Nefrologia. SuplementoExtraordinario. 2011;2(1):38-51.
  • Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, et al.Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney”. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27(3):1097-101.
  • Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi FK, et al.Acute kidney injury during leukocyte engraftment after autologous stem cell transplantation in patients with light-chain amyloidosis”. American journal of hematology. 2012;87(1):51-4.
  • Hogan MC, Masyuk TV, Page L, Holmes DR 3rd, Li X, Bergstralh EJ, Irazabal MV, Kim B, King BF, Glockner JF, Larusso NF, Torres VE. “Somatostatin analog therapy for severe polycystic liver disease: results after 2 years”. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2012;27(9):3532-9.
  • Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, et al.Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study”. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association. 2012.Sep 17.
  • Leung N, Gertz M, Kyle RA, Fervenza FC, Irazabal MV, Eirin A, et al. “Urinary Albumin Excretion Patterns of Patients with Cast Nephropathy and Other Monoclonal Gammopathy-Related Kidney Diseases”. Clinical journal of the American Society of Nephrology: CJASN. 2012. Sep 27.
  • Irazabal MV, Torres VE. “Experimental Therapies and Ongoing Clinical Trials to Slow Down Progression of ADPKD”. Curr Hypertens Rev. 2013 Feb;9(1):44-59.
  • Warner JD, Irazabal MV, Krishnamurthi G, King BF, Torres VE, and Erickson BJ. “Supervised Segmentation of Polycystic Kidneys: A New Application for Stereology Data” J Digit Imaging. 2014 Mar 18. [Epub ahead of print]
  • Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, Bae KT, Chapman AB, Grantham JJ, Mrug M, Hogan MC, El-Zoghby ZM, Harris PC, Erickson BJ, King BF, Torres VE, and the CRISP Investigators. “Imaging classification of ADPKD: A simple prognostic biomarker” J Am Soc Nephrol. 2014 Jun 5. pii: ASN.2013101138. [Epub ahead of print]
  • LaRiviere WB, Irazabal MV, Torres VE. Novel therapeutic approaches in the treatment of Autosomal Dominant Polycystic Kidney Disease”(Under revision inTranslational Research)
  • Kline TL; Irazabal MV; Ebrahimi B; Hopp K; Lerman LO; Harris PC; King BF; Torres VE; Erickson BJ “Magnetization Transfer Imaging for Tissue Remodeling Analysis in a Murine Model of ADPKD” (Submitted to Magnetic Resonance in Medicine)
  • Irazabal MV; Mishra P; Torres VE; Macura SI “Use of UHF MRI in small rodent models of PKD for in vivo phenotyping and drug monitoring” (Under revision in JoVE)
  • Jung Y; Irazabal MV; Chebib F; Torres VE “Volume Regression of Native Polycystic Kidneys after Renal Transplantation” (In preparation)
  • Irazabal MV, Kline TL; Ebrahimi B; Hopp K; Macura S; Lerman LO; Harris PC; King BF; Torres VE; Erickson BJ. “Blood oxygen level dependent (BOLD) Imaging to Assess Disease Severity in Autosomal Dominant Polycystic Kidney Disease (In preparation)
  • Irazabal MV, Huston  J, Brown RD, Sundsbak JL, Rossetti S, Hogan MC, Harris PC, Torres VE. “Susceptibility to cerebral vasospasm in Autosomal Dominant Polycystic Kidney Disease” (In preparation Nephrol Dial Transplant).
  • Irazabal MV, Connolly HM, Hogan MC, Sundsbak JL, Rossetti S, Harris PC, Torres VE. “Congenital heart disease in Autosomal Dominant Polycystic Kidney Disease” (In preparation).
Book chapters:
  • Eirin A, Irazabal MV, Fervenza FC. “Membranous Nephropathy” Nephrology Secrets. 3rd edition. (ELSEVIER, 2011).
  • Irazabal MV, Torres VE. “Cystic diseases of the kidney” Clinical Genomics: Practical Applications in Adult Patient Care. McGraw Hill (ed); 2012.
  • Irazabal MV, Torres VE. “Complications of Polycystic Kidney Disease” POLYCYSTIC KIDNEY DISEASE. Future Medicine.
  • Irazabal MV, Torres VE. “Enfermedad Poliquística: clasificación, etiopatogenia, diagnóstico y actitudes terapéuticas”  NEFROLOGÍA CLÍNICA. 4th Edition. Editorial Médica Panamericana.
  • Irazabal MV, Harris PC, Torres VE. “Molecular genetic mechanisms in ADPKD” Molecular Pathology of Kidney Disease (in preparation) Springer.
  • Irazabal MV, Torres VE. “Vasopressin Receptor Antagonism” Polycystic Kidney Disease: Translating Mechanisms into Therapy (in preparation) Springer.
Abstracts:
  • Fervenza FC, Erickson SB, Nachman PH, Dillon JJ, Leung N, Hogan MC, Hickson LT, Anand B, Visich J, Irazabal MV, Eirin A, Cattran DC. “Pharmacokinetics (PK) of Rituximab in Idiopathic Membranous Nephropathy (IMN)” J Am Soc Nephrol Abstracts Issue 20: 2009(155).
  • Leung N, Irazabal MV, Eirin A, Gunderson HD, Fervenza FC. “Efficacy of Rasburicase in the Prevention of Acute Kidney Injury of Tumor Lysis Syndrome” J Am Soc Nephrol Abstracts Issue 20: 2009(328).
  • Irazabal MV, Eirin A, Lieske JC, Borland TM, Erickson SB, Dillon JJ, Nachman PH, Cattran DC, Fervenza FC. “Fractional Excretion of High and Low Molecular Weight Proteins Correlates with Response to Rituximab (RTX) Therapy in Patients with Idiopathic Membranous Nephropathy (MN): A Prospective Study” J Am Soc Nephrol Abstracts Issue 20: 2009(632).
  • Irazabal MV, Keryakos H, Eirin A, Dillon JJ, Cattran DC, Fervenza FC. “In Idiopathic Membranous Nephropathy (MN) Resistance to Rituximab Treatment Does Not Preclude Response to Cyclosporine or Cyclophosphamide” J Am Soc Nephrol Abstracts Issue 20: 2009(632-633).
  • Eirin A, Irazabal MV, Abraham RS, Erickson SB, Nachman PH, Lieske JC, Leung N, Dillon JJ, Cattran DC, Fervenza FC. “Quantification of B Cell and T Cell Subsets Do Not Predict Response to Rituximab Therapy in Patients with Idiopathic Membranous Nephropathy: A Prospective Study” J Am Soc Nephrol Abstracts Issue 20: 2009(635).
  • Fervenza FC, Erickson SB, Nachman PH, Dillon JJ, Leung N, Hogan MC, Hickson LT, Qazi Q, Bergstralh EJ, Irazabal MV, Erin A, Cattran DC. “Rituximab (RTX) in the Treatment of Idiopathic Membranous Nephropathy (IMN)” J Am Soc Nephrol Abstracts Issue 20: 2009(745).
  • Irazabal MV, Eirin A, Erickson SB, Leung N, Dillon JJ, Keryakos H, Cattran DC, Fervenza FC. “Long-Term Outcome of Patients with Membranous Nephropathy after Rituximab Therapy” J Am Soc Nephrol Abstracts Issue 20: 2009(745).
  • Eirin A, Irazabal MV, Erickson SB, Keryakos H, Fervenza FC. “Relapse of Nephrotic Syndrome after Rituximab Therapy in a Patient with Idiopathic Membranous Nephropathy” J Am Soc Nephrol Abstracts Issue 20: 2009(963).
  • Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U,  Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LT, and Cattran DC. “Rituximab (RTX) therapy in idiopathic membranous nephropathy (IMN): results at 2 years” Nephrol Dial Transplant Plus 2010 3(Supplement 3): iii275–iii547.
  • Leung N, Gertz MA, Dispenzieri A, Lacy MQ, Buadi F, Hayman SR, Dingli D, Hogan WJ, Irazabal MV, Eirin A, & Kumar S. “Engraftment syndrome presenting as acute renal failure in light chain amyloidosis patients after autologous stem cell transplantation” Amyloid, April 2010; 17(Suppl 1): 172.
  • Leung N, Irazabal MV, Eirin A, Lacy MQ, Dispenzieri A, Buadi FK, Zeldenrust SR, Hayman SR, Kumar S, Russell SJ, Kyle RA, Ramirez-Alvarado M, Sethi S, Erickson SB, Fervenza FC, & Gertz MA. “Differences in clinical presentation and outcomes of patients with vascular limited light chain amyloidosis (AL) versus diffuse Amyloid” April 2010; 17(Suppl 1): 173.
  • Eirin A, Irazabal MV, Gunderson HD and Leung N. “Evaluation of Low Dose Rasburicase In the Prevention of Renal Insufficiency and Dialysis After Chemotherapy” Blood 116(21), 2010: 2574
  • Irazabal MV, Eirin A, Gertz MA, Dispenzieri A, Kumar S, Buadi F, Lacy MQ, Hayman SR, Dingli D, Hogan WJ, and Leung N. “Acute Renal Failure Is a Common Presentation of Engraftment Syndrome In Light Chain Amyloidosis (AL) Patients After Autologous Stem Cell transplantation” Blood 116(21), 2010: 3468.
  • Irazabal MV, Torres VE, Hogan MC, Glockner J, King BF, Ofstie TG, Krasa HB, Ouyang J, Czerwiec FS. “Short-term effects of Tolvaptan on Renal Function and Volume in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)” J Am Soc Nephrol Abstracts Issue 21: 2010 (528).
  • Irazabal MV, Huston J, Kubly VJ, Rossetti S, Hogan M, Harris PC, Brown RD, Torres VE. “Follow-up of unruptured intracranial aneurysms (UIA) detected by presymptomatic screening in patients with autosomal dominant polycystic kidney disease (ADPKD)” J Am Soc Nephrol Abstracts Issue 21: 2010 (529).
  • Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LT, and Cattran DC. “Efficacy, Durability, and Immunological Analyses Following Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-year study” J Am Soc Nephrol Abstracts Issue 21: 2010(638).
  • Geetha D, Eirin A, True K, Irazabal MV, Specks U, Seo P, Nachman PH, and Fervenza FC. “A multicenter experience of kidney transplantation in ANCA-associated vasculitis (AAV) in the era of modern immunosuppression” J Am Soc Nephrol Abstracts Issue 21: 2010(804).
  • Geetha D, Eirin A, True K, Irazabal MV, Specks U, Seo P, Nachman PH, and Fervenza FC. “Renal Transplantation in ANCA associated vasculitis: Allograft Outcome and Vasculitis Relapse Rate” Clin Exp Immunol abstract supplement. 2011; (Suppl. 1), 50–67.
  • Beck LH, Fervenza FC, Bomback AS, Ayalon R, Irazabal MV, Eirin A, Cattran DC, Appel GB, Salant DJ. “Response of Anti-PLA2R to Adrenocorticotropic hormone (ACTH) Gel in Primary Membranous Nephropathy” J Am Soc Nephrol Abstracts Issue 22: 2011 (33).
  • Irazabal MV, Eirin A, Lieske J, Borland TM, Sethi S, Erickson SB, Dillon JJ, Nachman PH, Cattran DC, and Fervenza FC. J Am Soc Nephrol “Urinary biomarkers as predictors of response to rituximab in patients with membranous nephropathy” Abstracts Issue 22: 2011 (774).
  • Irazabal MV, Harmon A, Connolly HM, Hogan MC, Sundsbak JL, Rossetti S, Harris PC, Torres VE. “Congenital heart disease in Autosomal Dominant Polycystic Kidney Disease” J Am Soc Nephrol Abstracts Issue 22: 2011 (902).
  • Irazabal MV; Froemming, A.; Takahashi, N.; Kim, B.; Kawashima, A.; Harris, P.; Torres, V.; King, B. “The Genetics, Proteomics and Phenotypes of Autosomal Dominant Polycystic Kidney Disease” AJR May 2012 vol. 198 no. 5 Supplement, E628.
  • Beck LH, Fervenza FC, Bomback AS, Ayalon R, Irazabal MV, Eirin A, Cattran DC, Appel GB, and Salant DJ. “Response of Anti-PLA2R to Adrenocorticotropic hormone (ACTH) Gel in Primary Membranous Nephropathy” Nephrol Dial Transplant (2012) 27(Suppl 2): ii414–ii426.
  • Irazabal MV, Eirin A, Lieske J, Beck LH, Dillon JJ, Nachman PH, Sethi S, Erickson SB, Cattran DC, and Fervenza FC. “Low and high molecular weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study” Nephrol Dial Transplant (2012) 27(Suppl 2): ii182–ii196.
  • Hladunewich MA, Fervenza FC, Beck LH, Reich HN, Sethi S, Irazabal MV, Eirin A, Ayalon R, Cattran DC. “A Pilot Study to Determine Dose, Effectiveness and Depletion of Anti- PLA2R Antibodies of Adrenocorticotrophic Hormone (ACTH Acthar® Gel) in Subjects with Nephrotic Syndrome and Idiopathic Membranous Nephropathy (iMN)” J Am Soc Nephrol Abstracts Issue 23: 2012 (58).
  • Irazabal MV, Boertien WE, Landsittel D, Li J, Struck J, Flessner MF, Gansevoort RT, and Torres VE. “Urine Sodium Excretion and Plasma proANP as Markers of Disease Progression in ADPKD” J Am Soc Nephrol Abstracts Issue 23: 2012 (246).
  • Eirin A, Irazabal MV, Lieske J, Nasr S, Sethi S, Fervenza FC. “Dent’s Disease Presenting as Global Glomerulosclerosis” J Am Soc Nephrol Abstracts Issue 23: 2012 (366).
  • Eirin A, Irazabal MV, Fervenza FC, Sethi S. “Histiocytic Glomerulopathy associated with Macrophage Activating Syndrome” J Am Soc Nephrol Abstracts Issue 23: 2012 (537).
  • Rossetti S, Irazabal MV, Hopp K, Kubly VJ, Sundsbak JL, Hogan MC, Torres VE, and Harris PC. “Analysis of the Genomic Profile Associated with the Development of a Vascular Phenotype in Autosomal Dominant Polycystic Kidney Disease” J Am Soc Nephrol Abstracts Issue 23: 2012 (699).
  • Irazabal MV, Landsittel D, Chapman AB, Grantham JJ, Mrug M, Bae KT, Flessner MF, Bennett WM, Torres VE. Phosphorus and Disease Progression in Autosomal Dominant Polycystic Kidney Disease” J Am Soc Nephrol Abstracts Issue 23: 2012 (703).
  • Irazabal MV, Kubly VJ, Osborn SL, Harmon A, Crane JA, Bergstralh EJ, Erickson BJ, Torres VE, and King BF. “Comparison of CT and MRI methodologies to measure kidney volume in ADPKD” J Am Soc Nephrol Abstracts Issue 23: 2012 (703).
  • Warner JD, Irazabal MV, Erickson BJ, King BF, Bae KT, Grantham JJ, Chapman AB, Mrug M, Landsittel D, Flessner MF, Bennett WM, and Torres VE. “A new metric to predict Autosomal Dominant Polycystic Kidney Disease (ADPKD) progression: Cyst parenchyma surface area (CPSA)” J Am Soc Nephrol Abstracts Issue 23: 2012 (704).
  • Wang X, Ye H, Irazabal MV, Kumar R, Harris PC, Savica V, Torres VE. “Effect of Dietary Phosphate on the Progression of Polycystic Kidney Disease (PKD)” J Am Soc Nephrol Abstracts Issue 23: 2012 (948).
  • Irazabal MV; Huston J; Sykes AG; Takahashi N; Kawashima A; Erickson BJ; Torres VE; King BF. “Imaging of the renal and extrarrenal manifestations of Autosomal Dominant Polycystic Kidney Disease (ADPKD)” Accepted. Washington, DC. American Roentgen Ray Society annual meeting 2013.
  • Irazabal MV, Rangel LJ, Bergstralh EJ, Harmon AJ, Hogan MC, El-Zoghby Z, Harris PC, King BF, Torres VE. “Novel Imaging Classifi cation to Predict Functional Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)” J Am Soc Nephrol 24: 2013 (59A-60A).
  • Hopp K, Rossetti S, Irazabal MV, Paul BM, Sundsbak JL, Heyer CM, Harris PC. “Identification of Mosaic Mutations in Mild, Mutation Negative ADPKD Patients Using Next-Generation Sequencing” J Am Soc Nephrol 24: 2013 (58A-59A).
  • Hogan MC, Bergstralh EJ, Irazabal MV, Glockner J, Li X, Torres VE. “Analysis of Octreotide LAR Therapy after Four Years in Polycystic Liver and Kidney Disease” J Am Soc Nephrol 24: 2013 (689A).
  • Paul BM, Sundsbak JL, Heyer CM, Hopp K, Irazabal MV, Hogan MC, Kubly VJ, Torres VE, Harris PC. “In Vitro and Family Analysis to Assess the Significance of Indeterminate PKD1 Variants” J Am Soc Nephrol 24: 2013 (694A).
  • Warner JD, Irazabal MV, Erickson BJ, King BF, Bae KT, Grantham JJ, Chapman AB, Mrug M, Landsittel D, Flessner MF, Bennett WM, and Torres VE. “Cyst-Parenchyma Surface Area: A New Prognostic Image Feature for ADPKD”. Chicago, IL. Radiological Society of North America annual meeting 2013.
  • Warner JD, Irazabal MV, Krishnamurthi G, King BF, Torres VE, and Erickson BJ. “Supervised Segmentation of Polycystic Kidneys: A New Application for Stereology Data” Accepted. Dallas, TX. Society of Imaging Informatics in Medicine annual meeting, 2013.
  • Warner JD, Irazabal MV, Torres VE, King BF, and Erickson BJ. “Central vs peripheral cyst concentration as a prognostic biomarker for polycystic kidney disease”. SPIE Medical Imaging annual meeting 2014.
  • Irazabal MV, Kline TL; Ebrahimi B; Hopp K; Macura S; Lerman LO; Harris PC; King BF; Torres VE; Erickson BJ. “Blood oxygen level dependent (BOLD) Imaging to Assess Disease Severity in Autosomal Dominant Polycystic Kidney Disease (ADPKD” ASN 2014
  • Kline TL; Irazabal MV; Ebrahimi B; Hopp K; Lerman LO; Harris PC; King BF; Torres VE; Erickson BJ “Magnetization Transfer Imaging for Tissue Remodeling Analysis in a Murine Model of ADPKD” ASN 2014
  • Jung Y; Irazabal MV; Chebib F; Torres VE “Volume Regression of Native Polycystic Kidneys after Renal Transplantation” ASN 2014
  • Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE. “Effects of Hydration in Rodent Models of Polycystic Kidney Disease: Differences Between Rats and Mice” ASN 2014

 

 

Maria V Irazabal Mira

Assistant Professor


  • DEPARTMENT
  • COUNTRY USA